Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.37 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.37 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.37 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.37 |
| ▸ | IDO1 | P14902 | 1/20 | 0.37 |
| ▸ | TDO2 | P48775 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.36 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.35 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29976363 | 0.76 | ADRB2 (0.48) | IDO1TDO2CYP3A4CYP2D6SLC6A2 | |
| SCHEMBL230382 | 0.76 | ADRB2 (0.48) | IDO1TDO2CYP3A4CYP2D6SLC6A2 | |
| SCHEMBL4707443 | 0.75 | IGFBP3 (0.39) | HPGDHSD17B10KCNA5CYP19A1OPRM1 | |
| SCHEMBL8327525 | 0.75 | GAA (0.34) | HPGDHSD17B10GAACYP3A4CYP2D6 | |
| SCHEMBL11632311 | 0.73 | GAA (0.66) | HPGDHSD17B10KCNA5CYP19A1GAA | |
| SCHEMBL4707217 | 0.73 | CYP2C19 (0.45) | HPGDHSD17B10KCNA5CYP19A1OPRM1 | |
| SCHEMBL21550102 | 0.73 | NPC1 (0.39) | GAACYP3A4CYP2D6SLC6A2SLC6A4 | |
| SCHEMBL8745972 | 0.72 | HPGD (0.53) | HPGDHSD17B10KCNA5CYP19A1IDO1 | |
| SCHEMBL8690340 | 0.71 | SMN1; SMN2 (0.55) | KCNA5GAACYP3A4CYP2D6SLC6A2 | |
| SCHEMBL21549993 | 0.71 | OPRM1 (0.38) | OPRM1OPRL1GAACYP2D6IGFBP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7320994-B2 | Triazole derivatives as tachykinin receptor antagonists | ELI LILLY AND COMPANY (US) | 2008-01-22 | — | — | US | disclosed |
| EP-1501809-B1 | TRIAZOLE DERIVATIVES AS TACHYKININ RECEPTOR ANTAGONISTS | LILLY CO ELI (US) | 2008-01-16 | — | — | EP | disclosed |
| CN-1312136-C | Triazole derivatives as tachykinin receptor antagonists | LILLY CO ELI (US) | 2007-04-25 | — | — | CN | disclosed |
| US-20050239786-A1 | Triazole derivatives as tachykinin receptor antagonists | ELI LILLY COMPANY (US) | 2005-10-27 | — | — | US | disclosed |
| CN-1646502-A | Triazole derivatives as tachykinin receptor antagonists | LILLY CO ELI (US) | 2005-07-27 | — | — | CN | disclosed |
| EP-1501809-A1 | TRIAZOLE DERIVATIVES AS TACHYKININ RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2005-02-02 | — | — | EP | disclosed |
| WO-2003091226-A1 | TRIAZOLE DERIVATIVES AS TACHYKININ RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2003-11-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050239786-A1 | Triazole derivatives as tachykinin receptor antagonists | TACR1, TACR2, BDKRB1 | HPGD 1378/4885HSD17B10 3075/4885KCNA5 81/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.